733. Comparison of Air and Environmental Surfaces Contamination between Carbapenem-resistant Acinetobacter baumannii and KPC-producing Gram-negative Rods
Session: Oral Abstract Session: Preventing Hospital Transmission: Environment and Hands
Friday, October 9, 2015: 11:00 AM
Room: 7--AB

Background:

We aim to compare the differential degree of contamination from air and room surfaces among patients (pts) colonized with KPC-producing Gram-negative rods (KPC+) versus those colonized with carbapenem-resistant Acinetobacter baumannii (CRAB).

Methods:

This study was performed at a large hospital in Miami in all consecutive adult ICU pts detected to have either CRAB or KPC+ on surveillance cultures (rectal cultures, and if intubated also tracheal cultures). Air and environmental samples were obtained daily for 10 consecutive days or until discharged from hospital. Air was sampled using open blood agar plates (exchanged daily) placed above their headboards (2-ft from roof-tiles). Environmental surfaces sampled included bed rails, bedside tables, ventilator panels, and intravenous pumps.  Sterile Q-tips used to swab blood agar plates and environmental surfaces, were placed in 2mL TSB, incubated overnight, and then plated on MacConkey. Organisms were identified based on colony color, and morphology. Final identification was done by Vitek II. Carbapenem susceptibility for AB was checked using meropenem disks, and results were interpreted based on CLSI criteria. KPC production was determined using Hodge test.

Results:

During 5-months, 24 CRAB+ pts and 12 KPC+ pts were identified. In the CRAB+ group, out of the 184 air samples tested, 35 (19%) air samples grew CRAB. In the KPC+ group, out of the 92 air samples tested, 4 (4.3%) air samples grew KPC+ (p=0.001). Regarding environmental samples, the percentages of positive samples were 11.6% for CRAB+ pts, compared to 3.7% for the KPC+ pts (p<0.0001).

Conclusion:

Contamination of the ambient air and surfaces are higher among pts colonized with CRAB than among KPC+ colonized patients. 

                                                                                             

Luis Shimose, M.D.1, Eriko Masuda, MD2, Ana Berbel Caban, M.D.1, Maroun Sfeir, MD1, Maria X. Bueno, MD1, Dennise Depascale, MT3, Timothy Cleary, PhD4, Yohei Doi, MD, PhD5 and L. Silvia Munoz-Price, MD, PhD6, (1)Department of Medicine, University of Miami/ Jackson Memorial Hospital, Miami, FL, (2)Department of Medicine, LAC+USC Medical Center, Los Angeles, CA, (3)Infection Control, Jackson Memorial Hospital, Miami, FL, (4)Department of Pathology, University of Miami/ Jackson Memorial Hospital, Miami, FL, (5)University of Pittsburgh Medical Center, Pittsburgh, PA, (6)Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

Disclosures:

L. Shimose, None

E. Masuda, None

A. Berbel Caban, None

M. Sfeir, None

M. X. Bueno, None

D. Depascale, None

T. Cleary, None

Y. Doi, Shionogi: Scientific Advisor , Consulting fee
Merck: Investigator , Research grant
Melinta: Consultant , Consulting fee

L. S. Munoz-Price, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.